Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide in Hypothalamic Obesity After Craniopharyngioma Therapy
NCT02860923Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jan 2017
- Primary completion
- Jun 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypothalamic obesity (HO) comparing Exenatide with Placebo (2 arms). Primary endpoint: Change in Body Weight at 6 months. Started Jan 2017; status: completed.
02
Drugs
exenatide
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on NCT02860923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02860923.